Investigational drug shows promising results in Phase II study of aggressive, often fatal blood disorder with no approved therapies
Credit: MD Anderson Cancer Center A Phase I/II study, led by investigators at The University of Texas MD Anderson Cancer Center, reports an investigational drug...








